Lyme disease diagnosis often begins with blood testing, but the standard two-tier testing protocol has well-documented limitations. Understanding the tests and what they measure can help you communicate more effectively with your provider.
The Standard Two-Tier Test
The CDC-recommended testing protocol begins with an ELISA (enzyme-linked immunosorbent assay) test. If the ELISA is positive or equivocal, a Western Blot test is performed to confirm.
Limitations of Standard Testing
- Standard tests detect antibodies to Borrelia burgdorferi, not the bacteria itself
- Early Lyme disease may produce a false negative before the immune response develops
- Sensitivity is lower in early infection (estimated 29-40% in the first weeks)
- A negative test does not rule out Lyme disease
- Standard tests do not detect all strains of Borrelia
Alternative Testing Options
Some patients and providers explore testing through specialty laboratories that offer additional panels. These may include PCR testing, culture-based approaches, or expanded co-infection panels. Discuss these options with a Lyme-experienced provider.
Co-Infection Testing
Tick bites can transmit multiple pathogens simultaneously. Testing for co-infections such as Bartonella, Babesia, Ehrlichiosis, and Anaplasmosis may be recommended based on your clinical presentation and exposure history.
Clinical Diagnosis
Many experienced Lyme practitioners treat based on clinical presentation, symptom history, and exposure context, not exclusively on a positive blood test. If you have a compelling clinical history and a negative test, a Lyme-literate provider can evaluate your full picture.